Risk factors
Pelthos Therapeutics (PTHS) risk factors
Item 1A of every Pelthos Therapeutics Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
59 risks, 43 new, 50 dropped, 6 reworded since the prior year. Pelthos Therapeutics launched ZELSUVMI for molluscum contagiosum in July 2025, shifting its risk profile from clinical development to commercialization. The risk section emphasizes commercial execution, market acceptance, gross-to-net expenses, and ongoing internal control weaknesses.
Filed Mar 19, 2026 - FY2024 10-K risk factors
66 risks. Clinical stage biopharmaceutical company focusing on pain treatments and orphan diseases faces going concern doubts and material weaknesses in internal controls.
Filed Mar 27, 2025